


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:26Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405554" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405554</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>npjviruses</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Npj Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Npj Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">4679</journal-id><journal-id journal-id-type="pmc-domain">npjviruses</journal-id><journal-title-group><journal-title>npj Viruses</journal-title></journal-title-group><issn pub-type="epub">2948-1767</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405554</article-id><article-id pub-id-type="pmcid-ver">PMC12405554.1</article-id><article-id pub-id-type="pmcaid">12405554</article-id><article-id pub-id-type="pmcaiid">12405554</article-id><article-id pub-id-type="pmid">40897776</article-id><article-id pub-id-type="doi">10.1038/s44298-025-00149-2</article-id><article-id pub-id-type="publisher-id">149</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Distinct circulating autoantibodies are associated with COVID-19 hospitalization and SARS-CoV-2 neutralization activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jacob</surname><given-names initials="RA">Rajesh Abraham</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ajoge</surname><given-names initials="HO">Hannah O.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>D&#8217;Agostino</surname><given-names initials="MR">Michael R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shigayeva</surname><given-names initials="A">Altynay</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Banerjee</surname><given-names initials="A">Arinjay</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="MS">Matthew S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McGeer</surname><given-names initials="AJ">Allison J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mubareka</surname><given-names initials="S">Samira</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mossman</surname><given-names initials="K">Karen</given-names></name><address><email>mossk@mcmaster.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fa3aq29</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fa3aq29</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Department of Biochemistry and Biomedical Sciences, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/044790d95</institution-id><institution-id institution-id-type="GRID">grid.492573.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 6477 6457</institution-id><institution>Department of Microbiology, </institution><institution>Sinai Health System, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010x8gc63</institution-id><institution-id institution-id-type="GRID">grid.25152.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2154 235X</institution-id><institution>Vaccine and Infectious Disease Organization, </institution></institution-wrap>Saskatoon, SK Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Department of Laboratory Medicine and Pathobiology, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n0tzs53</institution-id><institution-id institution-id-type="ISNI">0000 0004 0469 1398</institution-id><institution>Sunnybrook Research Institute, </institution></institution-wrap>Toronto, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>3</volume><issue-id pub-id-type="pmc-issue-id">479226</issue-id><elocation-id>64</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="44298_2025_Article_149.pdf"/><abstract id="Abs1"><p id="Par1">SARS-CoV-2 infection disrupts the host&#8217;s immune system, altering autoimmune responses. This study investigated host autoreactivities in SARS-CoV-2 infections, their association with severe COVID-19, and the neutralizing antibody response. Circulating autoantibodies were detected in convalescent serum samples from unvaccinated SARS-CoV-2-infected patients. Clustering, correlation analysis, principal component analysis, and neural network modeling were used to explore the relationship between autoantibodies, hospitalization, and SARS-CoV-2 neutralization. The presence of one autoantibody correlated with the detection of multiple others. Anti-IFN&#945; antibodies were associated with elevated levels of anti-ENAs (extractable-nuclear antigen) but not with clinical outcome. COVID-19 hospitalization was significantly associated with the collective expression of autoantibodies targeting three ENAs: SSA/Ro52, Jo-1, and RNP. In contrast, autoantibodies targeting RNP/Sm, PCNA, Scl-70, and PL-12 were strongly associated with SARS-CoV-2 neutralization. In summary, this study has identified self-antigens targeted in hospitalized COVID-19 patients and highlights a novel association between the autoantibody response and the antiviral humoral response.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>RNA vaccines</kwd><kwd>SARS-CoV-2</kwd><kwd>Antibodies</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>OV4-170645</award-id><award-id>439999</award-id><award-id>OV4-170645</award-id><award-id>439999</award-id><award-id>439999</award-id><award-id>OV4-170645</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Autoantibodies that target various cellular components are linked to several autoimmune diseases (ADs). Over 100 ADs have been described and numerous autoepitopes identified, since the discovery of anti-DNA antibodies in systemic lupus erythematosus (SLE) patients in the 1940s<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Common targets of autoantibodies include antinuclear antibodies (ANA) targeting DNA and histones, extractable nuclear antigens (ENA) present in the nucleus and cytoplasm, phospholipids, and antineutrophil cytoplasmic antibodies (ANCA) directed against the cytoplasmic components of neutrophils. Preexisting autoantibodies can influence the course of infectious diseases, with viruses potentially triggering autoimmune conditions<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. Elevated autoantibody levels are observed in severe SARS-CoV-2 infected patients, although it remains unclear if autoantibodies are the cause or consequence of severe COVID-19<sup><xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref></sup>. During SARS-CoV-2 infection, autoantibodies are likely triggered by virus-induced cytokine storm<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>, molecular mimicry between viral and host proteins<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>, virus-induced T cell exhaustion<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>, and dysfunctional regulatory T cells<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. While ANAs can be elevated in long COVID-19 patients<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>, ANA positivity has also been shown to be substantially more prevalent than in the general population<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Furthermore, COVID-19 outpatients had an increased risk of developing inflammatory arthritis, connective tissue diseases, and intestinal-related AD in compared to inpatients, highlighting the complex relationship between autoantibodies and COVID-19<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par3">Type I interferon (IFN) induced innate immune responses are crucial for protective immunity as they reduce virus replication. Inborn defects in IFN pathway genes could impair critical antiviral interferon responses, increasing susceptibility to severe viral infections<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref></sup> Individuals with severe COVID-19 often harbor defects in TLR3, IRF3, and IRF7, critical for IFN responses<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref></sup>. Consistent with inborn genetic disorders, anti-IFN autoantibodies, which block IFN function, contribute to poorer clinical outcomes. These anti-IFN autoantibodies were first detected in patients treated with IFN&#946; for nasopharyngeal carcinoma in the early 1980s and are prevalent in autoimmune conditions like SLE and autoimmune polyendocrine syndrome type 1 (APS-1)<sup><xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref></sup>. Neutralizing anti-IFN autoantibodies are linked to a subset of critically ill COVID-19 patients with low levels of IFN<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Anti-IFN autoantibodies are found in ~10% of patients with critical COVID-19, are linked to multi-organ failure, and compromise antiviral defenses in the nasal mucosa, enabling virus dissemination<sup><xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref></sup>.</p><p id="Par4">Here, we detected 20 common autoantibody signatures, along with anti-IFN&#945; autoantibodies, using convalescent serum samples from unvaccinated, SARS-CoV-2-infected patients, and examined their relationship to disease severity. We further explored the correlation between circulating autoantibodies in the context of SARS-CoV-2 infection and identified a subset of anti-ENAs associated with hospitalization. Finally, we establish a new association between autoantibodies and the humoral immune response targeting the spike region of SARS-CoV-2 variants, mediating its neutralization.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Study population</title><p id="Par5">The clinical summary is outlined in Table <xref rid="Tab1" ref-type="table">1</xref>. The study cohort included 38 unvaccinated individuals infected with SARS-CoV-2. Serum samples were collected during the first and third Canadian pandemic waves in 2020 and 2021. Of the 38 patients, 63% (24/38) were managed as outpatients, while 37% (14/38) required hospitalization (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The median age was 56 and 66.5 years for non-hospitalized and hospitalized groups, respectively, with a higher proportion of females in the non-hospitalized group. Serum samples were collected at a median of 37 and 82 days following the first positive COVID-19 test for non-hospitalized and hospitalized groups, respectively. For the hospitalized group, the median time from onset of symptoms to hospital admission was 6 days. Common symptoms included fever, cough, and shortness of breath, with shortness of breath being more prevalent in hospitalized group. The hospitalized group had a higher prevalence of co-morbidities, including cardiac, vascular, pulmonary, and renal illnesses, as well as cancer and mental health conditions. The ICU group had four patients, two of whom required intubation.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Detection of autoantibodies in the cohort and clustering analysis.</title><p><bold>a</bold> Overview of cohort used in this study. <bold>b</bold> Fold increase in the levels of 20 clinically relevant autoantibodies and total IgG levels. Anti-ENA (black), anti-ANCA (red), anti-phospholipid (blue), anti-aminoacyl tRNA synthetase (green), anti-complement (brown), and total IgG (purple). <bold>c</bold> Clustered heatmap showing the clustering of autoantibodies. Clusters are horizontally separated using dashed lines. <bold>d</bold> Principal component analysis in ICU, hospitalized, and non-hospitalized groups. (red, ICU; green, hospitalized; blue, non-hospitalized) <bold>e</bold>&#8211;<bold>h</bold> Heatmap analysis on non-hospitalized, hospitalized, non-ICU hospitalized, and ICU groups.</p></caption><graphic id="d33e416" position="float" orientation="portrait" xlink:href="44298_2025_149_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical summary of patients from this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Summary</th><th colspan="1" rowspan="1">Non-hospitalized</th><th colspan="1" rowspan="1">Hospitalized</th><th colspan="1" rowspan="1">ICU</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Samples, no (%)</td><td colspan="1" rowspan="1">24 (63)</td><td colspan="1" rowspan="1">14 (37)</td><td colspan="1" rowspan="1">4 (10.5)</td></tr><tr><td colspan="1" rowspan="1">Age, median (IQR)</td><td colspan="1" rowspan="1">56 (34.3&#8211;63.0)</td><td colspan="1" rowspan="1">66.5 (56.5&#8211;85.3)</td><td colspan="1" rowspan="1">60 (55.5&#8211;64.5)</td></tr><tr><td colspan="1" rowspan="1">Sex, female/male</td><td colspan="1" rowspan="1">14/10</td><td colspan="1" rowspan="1">4/10</td><td colspan="1" rowspan="1">0/4</td></tr><tr><td colspan="1" rowspan="1">Days to sampling from first COVID-19 positive test, median (IQR)</td><td colspan="1" rowspan="1">37 (24.0&#8211;48.5)</td><td colspan="1" rowspan="1">82 (38.5&#8211;93.8)</td><td colspan="1" rowspan="1">62.5 (15.3&#8211;91.8)</td></tr><tr><td colspan="1" rowspan="1">Days to admission from onset of symptoms, median no (IQR)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">6 (2&#8211;9.8)</td><td colspan="1" rowspan="1">2.5 (0.5&#8211;5.3)</td></tr><tr><td colspan="4" rowspan="1">Symptom, no (%)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Asymptomatic</td><td colspan="1" rowspan="1">1 (4.2)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Fever</td><td colspan="1" rowspan="1">9 (37.5)</td><td colspan="1" rowspan="1">7 (50)</td><td colspan="1" rowspan="1">3 (75)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Cough</td><td colspan="1" rowspan="1">10 (41.7)</td><td colspan="1" rowspan="1">9 (64.3)</td><td colspan="1" rowspan="1">2 (50)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Shortness of breath</td><td colspan="1" rowspan="1">1 (4.2)</td><td colspan="1" rowspan="1">7 (50)</td><td colspan="1" rowspan="1">2 (50)</td></tr><tr><td colspan="4" rowspan="1">Co-morbidities, no (%)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Diabetes</td><td colspan="1" rowspan="1">3 (12.5)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Cardiac illnesses</td><td colspan="1" rowspan="1">2 (8.3)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Vascular illnesses</td><td colspan="1" rowspan="1">3 (12.5)</td><td colspan="1" rowspan="1">10 (71.4)</td><td colspan="1" rowspan="1">3 (75)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Pulmonary illnesses</td><td colspan="1" rowspan="1">1 (4.2)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Renal illnesses</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">1 (25)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Neuro-muscular illnesses</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Liver illnesses</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Gastro-intestinal illnesses</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Cancer conditions</td><td colspan="1" rowspan="1">1 (4.2)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Rheumatologic illnesses</td><td colspan="1" rowspan="1">1 (4.2)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Mental health diagnosis</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">3 (21.4)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#8195;Immuno-compromising condition</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">Intubation</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">2 (50)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Detection of autoimmune antibodies in convalescent sera</title><p id="Par6">We examined the relationship between autoimmune antibodies and hospitalization in SARS-CoV-2 infection by measuring autoantibody levels against 20 self-antigens associated with various clinical phenotypes, utilizing a magnetic bead-based multiplex approach. Of these, 75% (15 of 20) were ANAs targeting various nuclear components, including DNA and RNA. All ANAs targeted ENAs, a subgroup comprising non-chromatin nuclear proteins. The panel also included two ANCAs, one anti-aminoacyl tRNA synthetase (ARS) antibody, one antiphospholipid antibody, and one C1q antibody targeting the complement C1 complex. Sham control beads without any conjugated antigen were used for background fluorescence intensities. We observed a substantial variation in the prevalence of autoantibodies in our cohort with a 2.8- to 465.7-fold increase in autoantibody levels compared to sham-control beads (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). To determine whether variations in autoantibody levels were related to differences in IgG, we measured the total polyclonal IgG concentration (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). The mean IgG level was 1337&#8201;mg/dL (range, 1279&#8211;1397). There was no significant association between IgG levels and autoantibodies, except for CENP-B (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0357), suggesting that the variation in autoantibodies is largely independent of total IgG levels.</p></sec><sec id="Sec5"><title>Correlation matrix and clustering of autoantibodies</title><p id="Par7">We then evaluated the association between each of the 20 autoantibodies and their clustering patterns. Correlation matrix grouped the autoantibodies into four clusters (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). The first cluster (from the top) included five ANAs targeting various nuclear components (Ku, CENP-A, RNP/Sm, PCNA, and Scl-70) and an anti-ARS antibody, PL-12. Each of the six autoantibodies in this cluster strongly correlated with each other&#8212;intracluster correlation showed meaningful grouping of autoantibodies, providing further insight into those autoantibodies that are frequently co-expressed in this cohort. The second cluster contained two ANAs, Sm and PM/Scl-100, which significantly correlated with each other. The third cluster contained four ANAs (Ribosomal P, SSA/Ro52, RNP, and Jo-1) and an anti-phospholipid antibody, &#946;2-Glycoprotein, all of which significantly correlated with each other. The final cluster had seven autoantibodies: four ANAs (SSA/Ro60, SSB/La, Mi-2, and CENP-B), two ACNAs (Myeloperoxidase and Proteinase 3), and one anti-C1q antibody targeting the complement C1 component. The intra-cluster correlation was weakest for this cluster. Overall, the intracluster correlation analysis provided additional insight into patterns of autoantibody co-expression.</p><p id="Par8">In addition to the intra-cluster correlation, we observed significant inter-cluster correlations (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). While intra-cluster correlation helped identify autoantibodies that are closely related within specific groups, inter-cluster correlation allowed us to explore how autoantibodies in different clusters are connected. Autoantibodies from cluster 1 were strongly associated (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) with those in cluster 2 and weakly with cluster 4; however, no association was found between cluster 1 and cluster 3. The two ANAs in cluster 2 significantly correlated with the four ANAs in cluster 3, while eliciting a weak correlation with cluster 4. Finally, there was significant association between autoantibodies in cluster 3 and cluster 4. Our clustering data reveal that the presence of one autoantibody correlates with the detection of multiple other autoantibodies, suggesting a complex and heterogeneous autoimmune response in this cohort.</p></sec><sec id="Sec6"><title>Association of autoantibodies with COVID-19 progression</title><p id="Par9">Next, we performed principal component analysis (PCA) to reduce the dimensionality of the dataset and identify autoantibodies that are associated with COVID-19 hospitalization (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>). Dimension 1 (PC1) 1 and PC2 accounted for 40.2% and 21.2% of the total variance, respectively. However, PCA did not reveal any distinct separation between non-hospitalized, hospitalized, and ICU groups, indicating that autoantibodies by themselves are not associated with hospitalization in this cohort.</p><p id="Par10">Next, we focused on identifying signature patterns associated with disease progression using heatmap analysis (Fig. <xref rid="Fig1" ref-type="fig">1e&#8211;h</xref>). This enabled visualization of fold-changes in autoantibody levels across samples and identification of clustering patterns that might mediate hospitalization. Heatmap analyses were performed on four groups: non-hospitalized, hospitalized, non-ICU hospitalized, and ICU. While the non-hospitalized and non-ICU hospitalized groups showed interspersed clustering, there was a distinct separation of autoantibody clusters in the hospitalized and ICU groups. Notably, three ENAs from the third cluster (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>), SSA/Ro52, Jo-1, and RNP, clustered in the hospitalized and ICU groups (Fig. <xref rid="Fig1" ref-type="fig">1f, h</xref>). We noticed 3.8-, 3.5- and 1.9-fold increases in SSA/Ro52, Jo-1 and RNP levels, respectively, in hospitalized versus non-hospitalized groups (Table <xref rid="Tab2" ref-type="table">2</xref>), suggesting that these antigens could be targets in COVID-19-associated hospitalized patients and may be associated to ICU admission. Next, we investigated whether the systemic autoantibody response was associated with hospitalization (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The mean fold increase in autoantibody levels compared to sham-conjugated controls for the hospitalized and non-hospitalized groups is shown for each of the 20 autoantibodies (Table <xref rid="Tab2" ref-type="table">2</xref>). There was no significant difference in the fold-change of autoantibody levels while comparing the non-hospitalized group to the hospitalized group. However, the collective presence of SSA/Ro52, Jo-1, and RNP autoantibodies predicted hospitalization status with 62.5% accuracy using a neural network model (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). These findings indicate that this subset of autoantibodies could be synergistically associated with hospitalization, and future studies are needed to validate our findings.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Association of autoantibodies to COVID-19 hospitalization.</title><p><bold>a</bold> Mean autoantibody levels for each of the 20 autoantibodies between hospitalized and non-hospitalized groups. Statistical significance calculated using unpaired <italic toggle="yes">t</italic>-test (ns - not significant). <bold>b</bold> SSA/Ro52, Jo-1, and RNP autoantibodies collectively predicted hospitalization status in a neural network model.</p></caption><graphic id="d33e719" position="float" orientation="portrait" xlink:href="44298_2025_149_Fig2_HTML.jpg"/></fig><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Autoantibody levels in non-hospitalized and hospitalized category</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Autoantibodies</th><th colspan="1" rowspan="1">Mean fold change (non-hosp)</th><th colspan="1" rowspan="1">Mean fold change (hosp)</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Anti-neutrophil cytoplasmic antibody</td></tr><tr><td colspan="1" rowspan="1">&#8195;Myeloperoxidase</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Proteinase 3</td><td colspan="1" rowspan="1">46.1</td><td colspan="1" rowspan="1">23.1</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="3" rowspan="1">Anti-aminoacyl tRNA synthetase (ARS) antibody</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8195;PL-12</td><td colspan="1" rowspan="1">288.1</td><td colspan="1" rowspan="1">143.3</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">Anti-phospholipid antibody</td></tr><tr><td colspan="1" rowspan="1">&#8195;&#946;2-Glycoprotein</td><td colspan="1" rowspan="1">21.0</td><td colspan="1" rowspan="1">19.5</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">Anti-complement antibody</td></tr><tr><td colspan="1" rowspan="1">&#8195;C1q</td><td colspan="1" rowspan="1">312.5</td><td colspan="1" rowspan="1">125.7</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">Extractable nuclear antigen antibody</td></tr><tr><td colspan="1" rowspan="1">&#8195;Centromere protein A (CENP-A)</td><td colspan="1" rowspan="1">141.5</td><td colspan="1" rowspan="1">92.6</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Centromere protein B (CENP-B)</td><td colspan="1" rowspan="1">181.2</td><td colspan="1" rowspan="1">83.0</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Histidyl tRNA synthetase (Jo-1)</td><td colspan="1" rowspan="1">242.6</td><td colspan="1" rowspan="1">848.2</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Ku</td><td colspan="1" rowspan="1">299.1</td><td colspan="1" rowspan="1">163.8</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Mi-2</td><td colspan="1" rowspan="1">421.0</td><td colspan="1" rowspan="1">161.3</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Proliferating cell nuclear antigen (PCNA)</td><td colspan="1" rowspan="1">387.2</td><td colspan="1" rowspan="1">94.7</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Ribonucleoprotein (RNP)</td><td colspan="1" rowspan="1">302.5</td><td colspan="1" rowspan="1">563.8</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;DNA topoisomerase I (Scl-70)</td><td colspan="1" rowspan="1">410.8</td><td colspan="1" rowspan="1">143.0</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Smith (Sm)</td><td colspan="1" rowspan="1">74.6</td><td colspan="1" rowspan="1">53.2</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Robert-Antigen/Sjogren&#8217;s A (SSA/Ro52)</td><td colspan="1" rowspan="1">135.7</td><td colspan="1" rowspan="1">509.7</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Robert-Antigen/Sjogren&#8217;s A (SSA/Ro60)</td><td colspan="1" rowspan="1">40.4</td><td colspan="1" rowspan="1">29.1</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Sj&#246;gren syndrome antigen B (SSB/La)</td><td colspan="1" rowspan="1">303.5</td><td colspan="1" rowspan="1">67.8</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;RNP/Sm</td><td colspan="1" rowspan="1">20.6</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;Ribosomal protein P</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">ns</td></tr><tr><td colspan="1" rowspan="1">&#8195;PM/Scl-100</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">ns</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec7"><title>Detection of binding and neutralizing anti-IFN&#945; antibodies and their association with hospitalization</title><p id="Par11">Next, we investigated the role of circulating anti-IFN&#945; autoantibodies on COVID-19-related hospitalization. A549 cells were pre-treated with serial ten-fold dilutions of IFN&#945; and assayed for VSV-GFP replication to determine the minimal concentration required to maintain an antiviral state (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). IFN&#945; at concentrations of 0.01&#8201;ng/mL or higher resulted in a partial to complete antiviral state, with an IC<sub>50</sub> of 0.0125&#8201;ng/mL (95% CI of 0.01009 to 0.01580; Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). We next incubated A549 cells with 0.1 and 1&#8201;ng/mL IFN&#945; in the presence of serially diluted control anti-human mouse IgG1 monoclonal antibody (MMHA-2) that binds and neutralizes human IFN&#945; followed by VSV-GFP infection (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Treatment of A549 cells with IFN&#945; in the absence of MMHA-2 reduced VSV-GFP infection compared to untreated control (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> lower panel). Incubation of MMHA-2 with IFN&#945; resulted in a concentration-dependent increase in VSV-GFP infection for both IFN&#945; treatments (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> upper and middle panels), with an IC<sub>50</sub> of 16.6 and 119.7&#8201;ng/mL of MMHA-2 for neutralizing 0.1 and 1.0&#8201;ng/mL of IFN&#945;, respectively (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). We next evaluated if IFN&#945; autoantibodies in serum samples could dampen IFN&#945;-induced antiviral activity, with ID<sub>50</sub> values, referred to as a &#8220;neutralization score&#8221;, derived for each serum sample. Two patient samples had a substantial neutralization score with autoantibodies functionally neutralizing IFN&#945;. We further detected IFN&#945; binding antibodies using ELISA in 11% (4/38) of the cohort. Of these, three were in the non-hospitalized category, while one was admitted to the ICU. We did not notice an association between the presence of anti-IFN&#945; neutralizing or binding antibodies with hospitalization status (Fig. <xref rid="Fig3" ref-type="fig">3e&#8211;G</xref>). Corroborating these findings, PCA analysis showed no distinct clustering between serum samples with and without anti-IFN&#945; binding autoantibodies (Fig. <xref rid="Fig3" ref-type="fig">3h</xref>). Our data provide evidence that a subset of SARS-CoV-2 patients have binding IFN&#945; autoantibodies that are also capable of restricting an IFN&#945;-induced antiviral state.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Detection of anti-IFN&#945; antibodies and their association to hospitalization.</title><p><bold>a</bold> Activity of IFN&#945; on VSV-GFP replication in human A549 lung epithelial cells. <bold>b</bold> IC<sub>50</sub> determination of IFN&#945; activity from (<bold>a</bold>). <bold>c</bold> Anti-IFN&#945; neutralization assay using a control anti-IFN&#945; monoclonal neutralizing antibody (nAb), MMHA-2. <bold>d</bold> IC<sub>50</sub> determination of neutralization activity from (<bold>c</bold>). <bold>e</bold>, <bold>f</bold> Association of anti-IFN&#945; neutralizing antibodies to COVID-19 hospitalization. <bold>g</bold> Association of anti-IFN&#945; binding antibodies to COVID-19 hospitalization. <bold>h</bold> Principal component analysis in anti-IFN&#945; binding antibody positive and negative groups. (red, anti-IFN&#945; pos; blue, anti-IFN&#945; neg) <bold>i</bold> Heatmap analysis showing association between 20 autoantibodies and anti-IFN&#945; binding antibody. Statistical significance was calculated using an unpaired <italic toggle="yes">t</italic>-test (<bold>e</bold>&#8211;<bold>g</bold>) or Pearson coefficient (<bold>i</bold>).</p></caption><graphic id="d33e1036" position="float" orientation="portrait" xlink:href="44298_2025_149_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>Anti-IFN&#945; binding autoantibodies are strongly associated with ENA autoantibodies</title><p id="Par12">Next, we examined associations between binding anti-IFN&#945; autoantibodies and the other 20 autoantibodies (Fig. <xref rid="Fig3" ref-type="fig">3i</xref>). Notably, a positive correlation was noticed between binding anti-IFN&#945; autoantibodies and seven other autoantibodies. Among them, four (SSA/Ro52, RNP, PM/Scl-100, Jo-1) showed a strong correlation, indicating that the presence of anti-IFN&#945; autoantibodies is associated with a higher frequency of other autoantibodies.</p></sec><sec id="Sec9"><title>Circulating autoantibodies are associated with SARS-CoV-2 neutralization</title><p id="Par13">Last, we tested whether autoantibodies were associated with an increased humoral immune response against SARS-CoV-2. Five live SARS-CoV-2 isolates were used to determine neutralization activity: SB3 (ancestral), B.1.351 (beta), R.1 645 (R.1), B.1.617.2 (delta), and BA.5 (omicron)<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. SB3, R.1 645 and B.1.617.2 were neutralized by 63% (24/38), 76% (29/38) and 61% (23/38) of samples respectively at an ID<sub>50</sub>&#8201;&gt;&#8201;25 (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). In contrast, B.1.351 and BA.5 were neutralized by only 16% (6/38) and 13% (5/38) of samples respectively (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). B.1.351 was significantly more resistant to neutralization than SB3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0012), R.1 645 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001), and B.1.617.2 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0199). Similarly, BA.5 was significantly more resistant to neutralization than SB3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0006), R.1 645 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001), and B.1.617.2 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0181).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Association of autoantibodies to SARS-CoV-2 neutralization.</title><p><bold>a</bold> Sensitivity of SB3, B.1.351, R.1 645, B.1.617.2 and BA.5 variants to neutralizing antibodies (brown, SB3; green, B.1.351; blue, R.1 645; red, B.1.617.2; purple, BA.5). Statistical significance was calculated using an unpaired <italic toggle="yes">t</italic>-test (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001). <bold>b</bold> Circa plots to visualize association of the level of autoantibodies to SARS-CoV-2 neutralization (brown, SB3; green, B.1.351; blue, R.1 645; red, B.1.617.2; purple, BA.5). Statistical significance was calculated using Pearson coefficient (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001) <bold>c</bold>&#8211;<bold>g</bold> Principal component analysis in neutralizer and non-neutralizer groups (red, neutralizer; blue, non-neutralizer).</p></caption><graphic id="d33e1127" position="float" orientation="portrait" xlink:href="44298_2025_149_Fig4_HTML.jpg"/></fig></p><p id="Par14">To explore potential association between autoantibody levels and neutralization capacity, a correlation analysis was performed (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Strikingly, 12 of the 20 autoantibodies were significantly correlated with B.1.351 neutralization, suggesting that autoantibodies may enhance the neutralization activity against resistant SARS-CoV-2 isolates. Six ENAs (PCNA, Scl-70, RNP/Sm, CENP-A, Sm, and Ku), along with an aminoacyl-tRNA synthetase (PL-12), showed the strongest correlation (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001), suggesting that targeting of specific autoantigens is associated with significantly greater B.1.351 neutralization. Similarly, 10 autoantibodies were significantly correlated with B.1.617.2 neutralization, with RNP/Sm, PCNA, Scl-70, and PL-12 showing the strongest correlations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001). Interestingly, the four autoantibodies strongly associated with both B.1.351 and B.1.617.2 neutralization were grouped in cluster 1 (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Only two autoantibodies, proteinase 3 and CENP-B, were associated with BA.5 neutralization. There was no association observed for the other two sensitive SARS-CoV-2 isolates, SB3 and R.1 645. To further explore the relationship, we conducted PCA by categorizing samples as &#8220;neutralizers&#8221; (ID<sub>50</sub>&#8201;&gt;&#8201;25) or &#8220;non-neutralizers&#8221; (ID<sub>50</sub>&#8201;&lt;&#8201;25). There was no clustering between the two groups, indicating that autoantibodies collectively do not influence SARS-CoV-2 neutralization (Fig. <xref rid="Fig4" ref-type="fig">4c&#8211;g</xref>). These findings imply that autoantibodies targeting RNP/Sm, PCNA, Scl-70, and PL-12 correlates with SARS-CoV-2 neutralization activity.</p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p id="Par15">We detected levels of 20 clinically relevant, circulating autoantibodies frequently found in ADs using serum samples from unvaccinated, SARS-CoV-2-infected, recovered individuals and determined if autoreactivity was associated with severe COVID-19 using hospitalization as the primary criterion (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Although we observed the presence of a diverse repertoire of autoantibodies in acute SARS-CoV-2, there was no association between individual autoantibody frequency and hospitalization. However, the presence of three autoantibodies targeting SSA/Ro52, Jo-1, and RNP was collectively associated with hospitalization (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Our data indicate that the disruption of immunological tolerance is associated with hospitalization in SARS-CoV-2 acute infections and highlights the need for prospective studies to further investigate the association between infectious diseases and autoimmunity<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. Furthermore, 11% and 5% of our cohort had binding and neutralizing anti-IFN&#945; autoantibodies, respectively, with anti-IFN&#945; antibodies significantly associated with six ENAs and &#946;2-glycoprotein (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Finally, the presence of a subset of autoantibodies was found to be associated with enhanced neutralization of B.1.351, B.1.617.2, and BA.5 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par16">Transcriptomic and proteomic analyses from our group and others have highlighted the enrichment of antiviral responses and type I IFN signaling pathways leading to the expression of ISGs during SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref></sup>. Here, we demonstrate the presence of anti-IFN&#945; neutralizing antibodies in acute SARS-CoV-2 infection. The prevalence of these antibodies is slightly higher than the 1.5% observed in a blood bank study<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> and lower than the 10% observed in individuals with life-threatening COVID-19 pneumonia, of whom 94% were men<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. While systemic anti-IFN autoantibodies have been linked to higher viral loads and severe COVID-19, they serve to reduce excessive inflammation in APS-1 patients, leading to milder COVID-19 symptoms<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. The homeostatic function of anti-IFN&#945; neutralizing autoantibodies was demonstrated in the nasal mucosa of SARS-CoV-2 infected patients, where these autoantibodies appeared within weeks of infection, reduced excessive nasal IFN&#945; secretion and inflammation, thereby contributing to an efficient recovery<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Our data show that neutralizing anti-IFN&#945; antibodies are not driving hospitalization and may, in turn, be balancing the IFN activity to prevent excessive inflammation.</p><p id="Par17">Finally, we establish a correlation between SARS-CoV-2 neutralization and autoantibody response (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Although previous studies show an association between autoantibodies and anti-SARS-CoV-2 IgG targeting the receptor-binding domain (RBD), non-structural protein 1 (NSP1), and nucleocapsid protein<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>, it remained unclear if autoantibodies in COVID-19 patients associate with SARS-CoV-2 neutralization. Of the 20 autoantibodies examined, 12 were significantly associated with the neutralization of B.1.351, and 10 were significantly associated with B.1.617.2 neutralization, suggesting that the autoimmune response might modulate the anti-viral humoral immune response. A higher frequency of autoantibodies correlates with the ability to neutralize multiple human immunodeficiency virus-1 (HIV-1) subtypes, thereby broadening the neutralization spectrum in some HIV-1-infected individuals<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Similarly, anti-influenza antibodies from SLE patients have a higher avidity and neutralization capacity<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. The development of neutralizing antibodies may be controlled by immune tolerance mechanisms, as observed in HIV-1 and influenza virus infections, where antibodies develop long complementarity-determining region 3 (CDR3) loops and undergo extensive somatic hypermutation<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>. While factors such as infecting strain, timing of infection, viral load, and disease severity can influence the development of SARS-CoV-2 neutralization response<sup><xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref></sup>, future studies are needed to clarify our observed relationship between autoantibodies and neutralization.</p><p id="Par18">SARS-CoV-2 infections are associated with the development of new-onset IgG autoantibodies targeting numerous self-protein targets across a wide range of tissues<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Autoimmunity is a key feature of post-acute sequelae of COVID-19 (PASC), observed in approximately 10% of SARS-CoV-2 infections with persistent symptoms over 3 months after the initial infection<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Polyautoimmunity occurs in 62% of patients with PASC, characterized by the presence of ANAs detected over 12 months post-COVID-19 and correlating with neurological disorder intensity<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>. Although this observation suggests that autoantibodies could serve as biomarkers of PASC, limited evidence supports that targeting specific autoantibodies could reverse PASC. Interestingly, health records suggest that vaccination decreases the likelihood of developing AD post SARS-CoV-2 infection<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. The autoantibody levels were found to be stable in vaccinated individuals compared to acute COVID-19 patients; however, increased anti-SNURF antibodies have been reported following vaccination<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup>. Finally, it is noteworthy that the immunological mechanisms that drive virus-induced ADs are not exclusive to SARS-CoV-2; as infections with human cytomegalovirus, influenza virus, Epstein-Barr virus, and chikungunya virus have also been linked to autoimmunity<sup><xref ref-type="bibr" rid="CR68">68</xref>&#8211;<xref ref-type="bibr" rid="CR71">71</xref></sup>.</p><p id="Par19">A limitation of our study is the absence of longitudinal samples that would have been valuable to explore whether autoantibody levels were transient. Additionally, we did not have a direct comparison between our SARS-CoV-2 infection to an uninfected control group. However, seroprevalence data suggest that 76% of the Canadian population had infection-acquired antibodies from prior SARS-CoV-2 infections<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, making the establishment of a clear control group for comparison difficult. Some of our interpretations on hospitalization may be influenced by confounding factors&#8212;higher age, higher proportion of males, higher prevalence of vascular illnesses, and differences in sampling time. Another limitation is that we focused exclusively on the IFN&#945;2 subtype. Finally, limited serum sample availability precluded us from performing an IgG depletion in IFN-neutralizing patients.</p><p id="Par20">In conclusion, our findings suggest that the presence of autoantibodies in an acute setting may not independently lead to a pathological clinical phenotype; however, the presence of multiple, distinct autoantibodies could contribute to severe COVID-19. Identifying specific autoantibodies associated with severe COVID-19 provides valuable insights into biomarkers, and prospective studies are needed to explore this further. Notably, we observed that the generation of anti-IFN&#945; antibodies is correlated with the presence of several other autoantibodies, indicating a common feature governing the disruption of immune tolerance mechanism. Finally, our data showing a correlation between autoantibodies and SARS-CoV-2 neutralization in COVID-19 infections emphasize the need of further research to explore cross-reactivity of SARS-CoV-2 proteins with other autoepitopes and to determine if SARS-CoV-2-infected patients with AD develop a broader neutralizing antibody response.</p></sec><sec id="Sec11"><title>Methods</title><sec id="Sec12"><title>Human donors</title><p id="Par21">Informed consent was obtained for the collection of convalescent serum from 38 patients with laboratory-confirmed SARS-CoV-2 infection. This study was approved by Sunnybrook Research Institute (REB#2218) and Sinai Health System (REB# 02-0118-U and 05-0016-C) ethics boards.</p></sec><sec id="Sec13"><title>Cells and viruses</title><p id="Par22">Human A549 lung and monkey Vero E6 epithelial cells were cultured as described previously<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Vesicular stomatitis virus expressing green fluorescent protein (VSV-GFP) was used for IFN&#945; neutralization assays at MOI 1.0. SB3, an ancestral SARS-CoV-2 variant, and R.1 645, a variant under monitoring (VuM), were isolated and purified as described in refs. <sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>. The B.1.351 (beta), B.1.617.2 (delta), and BA.5 (omicron) were obtained from BEI Resources (Manassas, VA, United States). Experiments with SARS-CoV-2 were performed in a biosafety containment level 3 facility as approved by the institutional biosafety committee at McMaster University.</p></sec><sec id="Sec14"><title>Detection of autoantibodies</title><p id="Par23">Autoantibodies were detected using a multiplex panel (MilliporeSigma, Catalog # HAIAB-10K) following manufacturer&#8217;s guidelines. Briefly, to measure autoantibodies, beads were sonicated, vortexed, and thoroughly mixed. Assay plates were washed with 200&#8201;&#181;L of wash buffer for 10&#8201;min. After decanting the buffer, 25&#8201;&#956;L of assay buffer was added to each well, followed by 25&#8201;&#956;L of serum samples diluted 1:100 in assay buffer. Subsequently, 25&#8201;&#956;L of the mixed bead suspension was added to each well. Plates were incubated overnight at 4&#8201;&#176;C on a plate shaker. The following day, plates were washed three times with wash buffer. Then, 50&#8201;&#956;L of PE-conjugated IgG detection reagent was added to each well, and the plates were incubated at room temperature for 90&#8201;min. After incubation, plates were washed three times with wash buffer and the beads were resuspended in 150&#8201;&#956;L of drive fluid. The plate was shaken for 5&#8201;min to ensure uniform bead suspension. Fluorescence from labeled magnetic beads was measured with a MAGPIX instrument and data analyzed using xPONENT software. The specificity of the 20-plex panel ranged from 92% to 100% (manufacturer&#8217;s data), indicating minimal cross-reactivity. Sham control beads were used to measure background fluorescence intensities. These negative control beads (without any antigen) went through the same process of conjugation as the panel beads. Sham control beads exhibited low background fluorescence, with a median fluorescence intensity (MFI) of 36.6 (interquartile range: 23.7&#8211;82.0). Fold increases in MFI were calculated by dividing the MFI of each autoantibody with the MFI of sham-conjugated controls.</p></sec><sec id="Sec15"><title>Interferon treatment</title><p id="Par24">A549 cells were left untreated or treated with ten-fold serially diluted IFN&#945; (Catalog # I4276, Sigma-Aldrich). Cells were pre-treated for 6&#8201;h before infection with VSV-GFP at MOI 1.0. GFP was measured 24&#8201;h post-infection to determine initiation of virus replication.</p></sec><sec id="Sec16"><title>Anti-IFN&#945; neutralization assay</title><p id="Par25">The anti-IFN&#945; neutralizing monoclonal antibody MMHA-2 (Invitrogen, Catalog # 211002) or convalescent serum samples were serially diluted and incubated with 0.1 and 1.0&#8201;ng/mL IFN&#945; (Catalog # I4276, Sigma-Aldrich) for 2&#8201;h at 37&#8201;&#176;C. A549 cells were pre-treated with the antibody:IFN&#945; mixture for 6&#8201;h before infection with VSV-GFP at MOI 1.0. GFP was measured 24&#8201;h post-infection to determine initiation of virus replication.</p></sec><sec id="Sec17"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p id="Par26">Anti-IFN&#945; binding antibodies (catalog # 5018034, Invitrogen) and total IgG antibodies (catalog # BMS2091, Invitrogen) were determined using ELISA following manufacturer&#8217;s guidelines.</p></sec><sec id="Sec18"><title>SARS-CoV-2 neutralization assay</title><p id="Par27">Serially diluted serum samples were incubated with SARS-CoV-2 (150 PFU/well) at 37&#8201;&#176;C for 1&#8201;h before adding to pre-plated Vero E6 cells. Five days post-infection, luminescence was quantified with CellTiter-Glo 2.0 Reagent (catalog # G9243, Promega) using a BioTek Synergy H1 microplate reader. The luminescent signal, which was proportional to the amount of ATP present, was measured in Relative Light Units (RLU).</p></sec><sec id="Sec19"><title>Bioinformatics and statistical analysis</title><p id="Par28">Statistical power analysis was carried out in R using &#8220;pwr&#8221; package. This study is sufficiently powered, with most analyses having a power greater than 0.8 and a few marginal ones above 0.7. Correlation was executed in R using &#8220;rcorr&#8221; function from the &#8220;Hmisc&#8221; package. Heatmaps were generated using &#8220;pheatmap&#8221; package. &#8220;symnum,&#8221; an in-built function in R, was used to replace correlation coefficients with symbols based on the degree of relation. Principal component analysis (PCA) was executed in R using &#8220;prcomp&#8221; function from the &#8220;stats&#8221; package and visualized using &#8220;ggfortify&#8221; package. Neural network was executed in R using &#8220;neuralnet&#8221; package using 80% of the data for training and 20% for testing. Circa plots (<ext-link ext-link-type="uri" xlink:href="https://omgenomics.com/circa">https://omgenomics.com/circa</ext-link>) were used to visualize association of the level of autoantibodies with SARS-CoV-2 neutralization.</p><p id="Par29">Unpaired <italic toggle="yes">t</italic>-test with Welch&#8217;s correction was used to calculate differences between hospitalized and non-hospitalized groups. The correlation between autoantibody levels and anti-IFN&#945; antibody or SARS-CoV-2 neutralization was determined using the Pearson r product. Neutralization score was determined using a non-linear regression curve fit model. An unpaired <italic toggle="yes">t</italic>-test was used to compare the neutralization of the SARS-CoV-2 isolates. GraphPad Prism 10 was used for the above statistical tests.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by a COVID-19 response grant to KM from the Canadian Institutes of Health Research (CIHR #OV4-170645). MSM is supported by a CIHR COVID-19 rapid response grant, a CIHR new investigator award, and an Ontario early researcher award. Convalescent serum sample collection was supported by a COVID-19 response grant to AM and SM from the CIHR (#439999).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>R.A.J. and K.M. conceptualized and designed the study. R.A.J., A.S., A.J.M. and S.M. collected the data. M.R.D., A.B., M.S.M., A.J.M. and S.M. contributed resources. R.A.J. and H.O.A. analyzed and interpreted the data. R.A.J., H.O.A., and K.M. drafted the manuscript. All authors revised and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data used are available upon reasonable request to the corresponding author.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>WC</given-names></name><name name-style="western"><surname>Holman</surname><given-names>HR</given-names></name><name name-style="western"><surname>Deicher</surname><given-names>H</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>HG</given-names></name></person-group><article-title>Complement fixation with cell nuclei and DNA in lupus erythematosus</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1957</year><volume>96</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">13505796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3181/00379727-96-23545</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Robbins, W. C., Holman, H. R., Deicher, H. &amp; Kunkel, H. G. Complement fixation with cell nuclei and DNA in lupus erythematosus. <italic toggle="yes">Proc. Soc. Exp. Biol. Med.</italic><bold>96</bold>, 575&#8211;579 (1957).<pub-id pub-id-type="pmid">13505796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3181/00379727-96-23545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>A</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>B</given-names></name></person-group><article-title>Autoimmune diseases</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>345</volume><fpage>340</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">11484692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200108023450506</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Davidson, A. &amp; Diamond, B. Autoimmune diseases. <italic toggle="yes">N. Engl. J. Med.</italic><bold>345</bold>, 340&#8211;350 (2001).<pub-id pub-id-type="pmid">11484692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200108023450506</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>IR</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>MJ</given-names></name></person-group><article-title>Autoimmune epitopes: autoepitopes</article-title><source>Autoimmun. Rev.</source><year>2004</year><volume>3</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">15546795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2004.07.011</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mackay, I. R. &amp; Rowley, M. J. Autoimmune epitopes: autoepitopes. <italic toggle="yes">Autoimmun. Rev.</italic><bold>3</bold>, 487&#8211;492 (2004).<pub-id pub-id-type="pmid">15546795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2004.07.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mobasheri</surname><given-names>L</given-names></name><etal/></person-group><article-title>SARS-CoV-2 triggering autoimmune diseases</article-title><source>Cytokine</source><year>2022</year><volume>154</volume><fpage>155873</fpage><pub-id pub-id-type="pmid">35461172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155873</pub-id><pub-id pub-id-type="pmcid">PMC8979824</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mobasheri, L. et al. SARS-CoV-2 triggering autoimmune diseases. <italic toggle="yes">Cytokine</italic><bold>154</bold>, 155873 (2022).<pub-id pub-id-type="pmid">35461172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155873</pub-id><pub-id pub-id-type="pmcid">PMC8979824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Smatti, M. K. et al. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. <italic toggle="yes">Viruses</italic><bold>11</bold> (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v11080762</pub-id><pub-id pub-id-type="pmcid">PMC6723519</pub-id><pub-id pub-id-type="pmid">31430946</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Puel, A., Bastard, P., Bustamante, J. &amp; Casanova, J. L. Human autoantibodies underlying infectious diseases. <italic toggle="yes">J. Exp. Med.</italic><bold>219</bold>, 10.1084/jem.20211387 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20211387</pub-id><pub-id pub-id-type="pmcid">PMC8952682</pub-id><pub-id pub-id-type="pmid">35319722</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Wahab</surname><given-names>N</given-names></name><name name-style="western"><surname>Talathi</surname><given-names>S</given-names></name><name name-style="western"><surname>Lopez-Olivo</surname><given-names>MA</given-names></name><name name-style="western"><surname>Suarez-Almazor</surname><given-names>ME</given-names></name></person-group><article-title>Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis</article-title><source>Lupus</source><year>2018</year><volume>27</volume><fpage>572</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">28945149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0961203317731532</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Abdel-Wahab, N., Talathi, S., Lopez-Olivo, M. A. &amp; Suarez-Almazor, M. E. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. <italic toggle="yes">Lupus</italic><bold>27</bold>, 572&#8211;583 (2018).<pub-id pub-id-type="pmid">28945149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0961203317731532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>SE</given-names></name><etal/></person-group><article-title>New-onset IgG autoantibodies in hospitalized patients with COVID-19</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>5417</fpage><pub-id pub-id-type="pmid">34521836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25509-3</pub-id><pub-id pub-id-type="pmcid">PMC8440763</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. <italic toggle="yes">Nat. Commun.</italic><bold>12</bold>, 5417 (2021).<pub-id pub-id-type="pmid">34521836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25509-3</pub-id><pub-id pub-id-type="pmcid">PMC8440763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <italic toggle="yes">Sci. Transl. Med.</italic><bold>12</bold>, 10.1126/scitranslmed.abd3876 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abd3876</pub-id><pub-id pub-id-type="pmcid">PMC7724273</pub-id><pub-id pub-id-type="pmid">33139519</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodruff</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Dysregulated naive B cells and de novo autoreactivity in severe COVID-19</article-title><source>Nature</source><year>2022</year><volume>611</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">36044993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05273-0</pub-id><pub-id pub-id-type="pmcid">PMC9630115</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Woodruff, M. C. et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. <italic toggle="yes">Nature</italic><bold>611</bold>, 139&#8211;147 (2022).<pub-id pub-id-type="pmid">36044993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05273-0</pub-id><pub-id pub-id-type="pmcid">PMC9630115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Diverse functional autoantibodies in patients with COVID-19</article-title><source>Nature</source><year>2021</year><volume>595</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">34010947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03631-y</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. <italic toggle="yes">Nature</italic><bold>595</bold>, 283&#8211;288 (2021).<pub-id pub-id-type="pmid">34010947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03631-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L</given-names></name></person-group><article-title>The cytokine storm and COVID-19</article-title><source>J. Med Virol.</source><year>2021</year><volume>93</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">32592501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26232</pub-id><pub-id pub-id-type="pmcid">PMC7361342</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hu, B., Huang, S. &amp; Yin, L. The cytokine storm and COVID-19. <italic toggle="yes">J. Med Virol.</italic><bold>93</bold>, 250&#8211;256 (2021).<pub-id pub-id-type="pmid">32592501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26232</pub-id><pub-id pub-id-type="pmcid">PMC7361342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>C</given-names></name></person-group><article-title>Cytokine storm induced by SARS-CoV-2</article-title><source>Clin. Chim. Acta</source><year>2020</year><volume>509</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">32531256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2020.06.017</pub-id><pub-id pub-id-type="pmcid">PMC7283076</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Song, P., Li, W., Xie, J., Hou, Y. &amp; You, C. Cytokine storm induced by SARS-CoV-2. <italic toggle="yes">Clin. Chim. Acta</italic><bold>509</bold>, 280&#8211;287 (2020).<pub-id pub-id-type="pmid">32531256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2020.06.017</pub-id><pub-id pub-id-type="pmcid">PMC7283076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adiguzel</surname><given-names>Y</given-names></name></person-group><article-title>Molecular mimicry between SARS-CoV-2 and human proteins</article-title><source>Autoimmun. Rev.</source><year>2021</year><volume>20</volume><fpage>102791</fpage><pub-id pub-id-type="pmid">33610750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2021.102791</pub-id><pub-id pub-id-type="pmcid">PMC7890341</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Adiguzel, Y. Molecular mimicry between SARS-CoV-2 and human proteins. <italic toggle="yes">Autoimmun. Rev.</italic><bold>20</bold>, 102791 (2021).<pub-id pub-id-type="pmid">33610750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2021.102791</pub-id><pub-id pub-id-type="pmcid">PMC7890341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arevalo-Cortes</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodriguez-Pinto</surname><given-names>D</given-names></name><name name-style="western"><surname>Aguilar-Ayala</surname><given-names>L</given-names></name></person-group><article-title>Evidence for molecular mimicry between SARS-CoV-2 and human antigens: implications for autoimmunity in COVID-19</article-title><source>Autoimmune Dis.</source><year>2024</year><volume>2024</volume><fpage>8359683</fpage><pub-id pub-id-type="pmid">39247752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/8359683</pub-id><pub-id pub-id-type="pmcid">PMC11380714</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Arevalo-Cortes, A., Rodriguez-Pinto, D. &amp; Aguilar-Ayala, L. Evidence for molecular mimicry between SARS-CoV-2 and human antigens: implications for autoimmunity in COVID-19. <italic toggle="yes">Autoimmune Dis.</italic><bold>2024</bold>, 8359683 (2024).<pub-id pub-id-type="pmid">39247752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/8359683</pub-id><pub-id pub-id-type="pmcid">PMC11380714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>B</given-names></name><etal/></person-group><article-title>Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19)</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>827</fpage><pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Diao, B. et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). <italic toggle="yes">Front. Immunol.</italic><bold>11</bold>, 827 (2020).<pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Kusnadi, A. et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. <italic toggle="yes">Sci. Immunol.</italic><bold>6</bold>, 10.1126/sciimmunol.abe4782 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abe4782</pub-id><pub-id pub-id-type="pmcid">PMC8101257</pub-id><pub-id pub-id-type="pmid">33478949</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves-Pereira</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases</article-title><source>Immunology</source><year>2023</year><volume>168</volume><fpage>684</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">36349514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.13603</pub-id><pub-id pub-id-type="pmcid">PMC9877711</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Goncalves-Pereira, M. H. et al. Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases. <italic toggle="yes">Immunology</italic><bold>168</bold>, 684&#8211;696 (2023).<pub-id pub-id-type="pmid">36349514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.13603</pub-id><pub-id pub-id-type="pmcid">PMC9877711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meckiff</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T Cells in COVID-19</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1340</fpage><lpage>1353.e1316</lpage><pub-id pub-id-type="pmid">33096020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7534589</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T Cells in COVID-19. <italic toggle="yes">Cell</italic><bold>183</bold>, 1340&#8211;1353.e1316 (2020).<pub-id pub-id-type="pmid">33096020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7534589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Son, K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. <italic toggle="yes">Eur. Respir J.</italic><bold>61</bold>, 10.1183/13993003.00970-2022 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00970-2022</pub-id><pub-id pub-id-type="pmcid">PMC9515477</pub-id><pub-id pub-id-type="pmid">36137590</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seessle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">34223884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab611</pub-id><pub-id pub-id-type="pmcid">PMC8394862</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Seessle, J. et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. <italic toggle="yes">Clin. Infect. Dis.</italic><bold>74</bold>, 1191&#8211;1198 (2022).<pub-id pub-id-type="pmid">34223884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab611</pub-id><pub-id pub-id-type="pmcid">PMC8394862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peluso</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Munter</surname><given-names>SE</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>SG</given-names></name><name name-style="western"><surname>Henrich</surname><given-names>TJ</given-names></name></person-group><article-title>Lack of antinuclear antibodies in convalescent coronavirus disease 2019 patients with persistent symptoms</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>2083</fpage><lpage>2084</lpage><pub-id pub-id-type="pmid">34617982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab890</pub-id><pub-id pub-id-type="pmcid">PMC9187313</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Peluso, M. J., Thomas, I. J., Munter, S. E., Deeks, S. G. &amp; Henrich, T. J. Lack of antinuclear antibodies in convalescent coronavirus disease 2019 patients with persistent symptoms. <italic toggle="yes">Clin. Infect. Dis.</italic><bold>74</bold>, 2083&#8211;2084 (2022).<pub-id pub-id-type="pmid">34617982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciab890</pub-id><pub-id pub-id-type="pmcid">PMC9187313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study</article-title><source>EClinicalMedicine</source><year>2023</year><volume>56</volume><fpage>101783</fpage><pub-id pub-id-type="pmid">36643619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101783</pub-id><pub-id pub-id-type="pmcid">PMC9830133</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Chang, R. et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. <italic toggle="yes">EClinicalMedicine</italic><bold>56</bold>, 101783 (2023).<pub-id pub-id-type="pmid">36643619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101783</pub-id><pub-id pub-id-type="pmcid">PMC9830133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>HK</given-names></name><etal/></person-group><article-title>Severe influenza pneumonitis in children with inherited TLR3 deficiency</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>2038</fpage><lpage>2056</lpage><pub-id pub-id-type="pmid">31217193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20181621</pub-id><pub-id pub-id-type="pmcid">PMC6719423</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lim, H. K. et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. <italic toggle="yes">J. Exp. Med.</italic><bold>216</bold>, 2038&#8211;2056 (2019).<pub-id pub-id-type="pmid">31217193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20181621</pub-id><pub-id pub-id-type="pmcid">PMC6719423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bucciol</surname><given-names>G</given-names></name><name name-style="western"><surname>Desmet</surname><given-names>L</given-names></name></person-group><article-title>Leuven laboratory of inborn errors of, I., Corveleyn, A. &amp; Meyts, I. Pathogenic P554S Variant in TLR3 in a patient with severe influenza pneumonia</article-title><source>J. Clin. Immunol.</source><year>2022</year><volume>42</volume><fpage>430</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">34813006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-021-01172-7</pub-id><pub-id pub-id-type="pmcid">PMC8609169</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Bucciol, G. &amp; Desmet, L. Leuven laboratory of inborn errors of, I., Corveleyn, A. &amp; Meyts, I. Pathogenic P554S Variant in TLR3 in a patient with severe influenza pneumonia. <italic toggle="yes">J. Clin. Immunol.</italic><bold>42</bold>, 430&#8211;432 (2022).<pub-id pub-id-type="pmid">34813006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-021-01172-7</pub-id><pub-id pub-id-type="pmcid">PMC8609169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>SY</given-names></name></person-group><article-title>Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity</article-title><source>Hum. Genet.</source><year>2020</year><volume>139</volume><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">32040615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-020-02127-5</pub-id><pub-id pub-id-type="pmcid">PMC7739442</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhang, S. Y. Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity. <italic toggle="yes">Hum. Genet.</italic><bold>139</bold>, 911&#8211;918 (2020).<pub-id pub-id-type="pmid">32040615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-020-02127-5</pub-id><pub-id pub-id-type="pmcid">PMC7739442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>HK</given-names></name><etal/></person-group><article-title>TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>1888</fpage><lpage>1897</lpage><pub-id pub-id-type="pmid">25339207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000999</pub-id><pub-id pub-id-type="pmcid">PMC4248460</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lim, H. K. et al. TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk. <italic toggle="yes">Neurology</italic><bold>83</bold>, 1888&#8211;1897 (2014).<pub-id pub-id-type="pmid">25339207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000999</pub-id><pub-id pub-id-type="pmcid">PMC4248460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity</article-title><source>J. Exp. Med.</source><year>2011</year><volume>208</volume><fpage>2083</fpage><lpage>2098</lpage><pub-id pub-id-type="pmid">21911422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20101568</pub-id><pub-id pub-id-type="pmcid">PMC3182056</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Guo, Y. et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. <italic toggle="yes">J. Exp. Med.</italic><bold>208</bold>, 2083&#8211;2098 (2011).<pub-id pub-id-type="pmid">21911422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20101568</pub-id><pub-id pub-id-type="pmcid">PMC3182056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Chen, J. et al. Inborn errors of TLR3- or MDA5-dependent type I IFN immunity in children with enterovirus rhombencephalitis. <italic toggle="yes">J. Exp. Med.</italic><bold>218</bold>, 10.1084/jem.20211349 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20211349</pub-id><pub-id pub-id-type="pmcid">PMC8570298</pub-id><pub-id pub-id-type="pmid">34726731</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamborn</surname><given-names>IT</given-names></name><etal/></person-group><article-title>Recurrent rhinovirus infections in a child with inherited MDA5 deficiency</article-title><source>J. Exp. Med.</source><year>2017</year><volume>214</volume><fpage>1949</fpage><lpage>1972</lpage><pub-id pub-id-type="pmid">28606988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20161759</pub-id><pub-id pub-id-type="pmcid">PMC5502429</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lamborn, I. T. et al. Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. <italic toggle="yes">J. Exp. Med.</italic><bold>214</bold>, 1949&#8211;1972 (2017).<pub-id pub-id-type="pmid">28606988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20161759</pub-id><pub-id pub-id-type="pmcid">PMC5502429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Functional IRF3 deficiency in a patient with herpes simplex encephalitis</article-title><source>J. Exp. Med.</source><year>2015</year><volume>212</volume><fpage>1371</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">26216125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20142274</pub-id><pub-id pub-id-type="pmcid">PMC4548062</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Andersen, L. L. et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. <italic toggle="yes">J. Exp. Med.</italic><bold>212</bold>, 1371&#8211;1379 (2015).<pub-id pub-id-type="pmid">26216125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20142274</pub-id><pub-id pub-id-type="pmcid">PMC4548062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>N</given-names></name><etal/></person-group><article-title>Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency</article-title><source>J. Exp. Med.</source><year>2018</year><volume>215</volume><fpage>2567</fpage><lpage>2585</lpage><pub-id pub-id-type="pmid">30143481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20180628</pub-id><pub-id pub-id-type="pmcid">PMC6170168</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hernandez, N. et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. <italic toggle="yes">J. Exp. Med.</italic><bold>215</bold>, 2567&#8211;2585 (2018).<pub-id pub-id-type="pmid">30143481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20180628</pub-id><pub-id pub-id-type="pmcid">PMC6170168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciancanelli</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">25814066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa1578</pub-id><pub-id pub-id-type="pmcid">PMC4431581</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ciancanelli, M. J. et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. <italic toggle="yes">Science</italic><bold>348</bold>, 448&#8211;453 (2015).<pub-id pub-id-type="pmid">25814066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa1578</pub-id><pub-id pub-id-type="pmcid">PMC4431581</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <italic toggle="yes">Science</italic><bold>370</bold>, 10.1126/science.abd4570 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd4570</pub-id><pub-id pub-id-type="pmcid">PMC7857407</pub-id><pub-id pub-id-type="pmid">32972995</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matuozzo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19</article-title><source>Genome Med.</source><year>2023</year><volume>15</volume><fpage>22</fpage><pub-id pub-id-type="pmid">37020259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-023-01173-8</pub-id><pub-id pub-id-type="pmcid">PMC10074346</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Matuozzo, D. et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. <italic toggle="yes">Genome Med.</italic><bold>15</bold>, 22 (2023).<pub-id pub-id-type="pmid">37020259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-023-01173-8</pub-id><pub-id pub-id-type="pmcid">PMC10074346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saheb Sharif-Askari</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multiple inborn errors of type I IFN immunity in a 33-year-old male with a fatal case of COVID-19</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e29338</fpage><pub-id pub-id-type="pmid">38665565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e29338</pub-id><pub-id pub-id-type="pmcid">PMC11043952</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Saheb Sharif-Askari, N. et al. Multiple inborn errors of type I IFN immunity in a 33-year-old male with a fatal case of COVID-19. <italic toggle="yes">Heliyon</italic><bold>10</bold>, e29338 (2024).<pub-id pub-id-type="pmid">38665565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e29338</pub-id><pub-id pub-id-type="pmcid">PMC11043952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Kholaiq, H. et al. Human Genetic and immunological determinants of SARS-CoV-2 infection and multisystem inflammatory syndrome in children. <italic toggle="yes">Clin. Exp. Immunol.</italic>10.1093/cei/uxae062 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cei/uxae062</pub-id><pub-id pub-id-type="pmcid">PMC11771195</pub-id><pub-id pub-id-type="pmid">39028583</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panem</surname><given-names>S</given-names></name><name name-style="western"><surname>Check</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>D</given-names></name><name name-style="western"><surname>Vilcek</surname><given-names>J</given-names></name></person-group><article-title>Antibodies to alpha-interferon in a patient with systemic lupus erythematosus</article-title><source>J. Immunol.</source><year>1982</year><volume>129</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">6177744</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Panem, S., Check, I. J., Henriksen, D. &amp; Vilcek, J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. <italic toggle="yes">J. Immunol.</italic><bold>129</bold>, 1&#8211;3 (1982).<pub-id pub-id-type="pmid">6177744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1</article-title><source>PLoS Med.</source><year>2006</year><volume>3</volume><fpage>e292</fpage><pub-id pub-id-type="pmid">16756392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0030292</pub-id><pub-id pub-id-type="pmcid">PMC1475656</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Levin, M. Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1. <italic toggle="yes">PLoS Med.</italic><bold>3</bold>, e292 (2006).<pub-id pub-id-type="pmid">16756392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0030292</pub-id><pub-id pub-id-type="pmcid">PMC1475656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallbracht</surname><given-names>A</given-names></name><name name-style="western"><surname>Treuner</surname><given-names>J</given-names></name><name name-style="western"><surname>Flehmig</surname><given-names>B</given-names></name><name name-style="western"><surname>Joester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Niethammer</surname><given-names>D</given-names></name></person-group><article-title>Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon</article-title><source>Nature</source><year>1981</year><volume>289</volume><fpage>496</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">6162104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/289496a0</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Vallbracht, A., Treuner, J., Flehmig, B., Joester, K. E. &amp; Niethammer, D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. <italic toggle="yes">Nature</italic><bold>289</bold>, 496&#8211;497 (1981).<pub-id pub-id-type="pmid">6162104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/289496a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadjadj</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">32661059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmcid">PMC7402632</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. <italic toggle="yes">Science</italic><bold>369</bold>, 718&#8211;724 (2020).<pub-id pub-id-type="pmid">32661059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmcid">PMC7402632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trouillet-Assant</surname><given-names>S</given-names></name><etal/></person-group><article-title>Type I IFN immunoprofiling in COVID-19 patients</article-title><source>J. Allergy Clin. Immunol.</source><year>2020</year><volume>146</volume><fpage>206</fpage><lpage>208 e202</lpage><pub-id pub-id-type="pmid">32360285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2020.04.029</pub-id><pub-id pub-id-type="pmcid">PMC7189845</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Trouillet-Assant, S. et al. Type I IFN immunoprofiling in COVID-19 patients. <italic toggle="yes">J. Allergy Clin. Immunol.</italic><bold>146</bold>, 206&#8211;208 e202 (2020).<pub-id pub-id-type="pmid">32360285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2020.04.029</pub-id><pub-id pub-id-type="pmcid">PMC7189845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <italic toggle="yes">Science</italic><bold>370</bold>, eabd4585 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd4585</pub-id><pub-id pub-id-type="pmcid">PMC7857397</pub-id><pub-id pub-id-type="pmid">32972996</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <italic toggle="yes">Sci. Immunol.</italic><bold>6</bold>, 10.1126/sciimmunol.abl4340 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abl4340</pub-id><pub-id pub-id-type="pmcid">PMC8521484</pub-id><pub-id pub-id-type="pmid">34413139</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koning</surname><given-names>R</given-names></name><etal/></person-group><article-title>Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients</article-title><source>Intens. Care Med.</source><year>2021</year><volume>47</volume><fpage>704</fpage><lpage>706</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-021-06392-4</pub-id><pub-id pub-id-type="pmcid">PMC8034036</pub-id><pub-id pub-id-type="pmid">33835207</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Koning, R. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. <italic toggle="yes">Intens. Care Med.</italic><bold>47</bold>, 704&#8211;706 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-021-06392-4</pub-id><pub-id pub-id-type="pmcid">PMC8034036</pub-id><pub-id pub-id-type="pmid">33835207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients</article-title><source>Clin. Transl. Immunol.</source><year>2021</year><volume>10</volume><fpage>e1327</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cti2.1327</pub-id><pub-id pub-id-type="pmcid">PMC8370568</pub-id><pub-id pub-id-type="pmid">34429968</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Goncalves, D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. <italic toggle="yes">Clin. Transl. Immunol.</italic><bold>10</bold>, e1327 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cti2.1327</pub-id><pub-id pub-id-type="pmcid">PMC8370568</pub-id><pub-id pub-id-type="pmid">34429968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Lopez, J. et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. <italic toggle="yes">J. Exp. Med.</italic><bold>218</bold>, 10.1084/jem.20211211 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20211211</pub-id><pub-id pub-id-type="pmcid">PMC8352718</pub-id><pub-id pub-id-type="pmid">34357402</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacob</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Sensitivity to neutralizing antibodies and resistance to type I interferons in SARS-CoV-2 R.1 lineage variants, Canada</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>1386</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">37308158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2907.230198</pub-id><pub-id pub-id-type="pmcid">PMC10310370</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Jacob, R. A. et al. Sensitivity to neutralizing antibodies and resistance to type I interferons in SARS-CoV-2 R.1 lineage variants, Canada. <italic toggle="yes">Emerg. Infect. Dis.</italic><bold>29</bold>, 1386&#8211;1396 (2023).<pub-id pub-id-type="pmid">37308158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2907.230198</pub-id><pub-id pub-id-type="pmcid">PMC10310370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name><etal/></person-group><article-title>Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>102477</fpage><pub-id pub-id-type="pmid">33937724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102477</pub-id><pub-id pub-id-type="pmcid">PMC8074517</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Banerjee, A. et al. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. <italic toggle="yes">iScience</italic><bold>24</bold>, 102477 (2021).<pub-id pub-id-type="pmid">33937724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102477</pub-id><pub-id pub-id-type="pmcid">PMC8074517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatton</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7092</fpage><pub-id pub-id-type="pmid">34876592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27318-0</pub-id><pub-id pub-id-type="pmcid">PMC8651658</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Hatton, C. F. et al. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. <italic toggle="yes">Nat. Commun.</italic><bold>12</bold>, 7092 (2021).<pub-id pub-id-type="pmid">34876592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27318-0</pub-id><pub-id pub-id-type="pmcid">PMC8651658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazquez</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma</article-title><source>J. Clin. Immunol.</source><year>2021</year><volume>41</volume><fpage>1169</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">34009544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-021-01060-0</pub-id><pub-id pub-id-type="pmcid">PMC8132742</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Vazquez, S. E. et al. Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma. <italic toggle="yes">J. Clin. Immunol.</italic><bold>41</bold>, 1169&#8211;1171 (2021).<pub-id pub-id-type="pmid">34009544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-021-01060-0</pub-id><pub-id pub-id-type="pmcid">PMC8132742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Meisel, C. et al. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. <italic toggle="yes">J. Clin. Investig.</italic><bold>131</bold>, 10.1172/JCI150867 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI150867</pub-id><pub-id pub-id-type="pmcid">PMC8279584</pub-id><pub-id pub-id-type="pmid">34061776</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babcock</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19</article-title><source>Sci. Transl. Med.</source><year>2024</year><volume>16</volume><fpage>eadq1789</fpage><pub-id pub-id-type="pmid">39504354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adq1789</pub-id><pub-id pub-id-type="pmcid">PMC11924959</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Babcock, B. R. et al. Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19. <italic toggle="yes">Sci. Transl. Med.</italic><bold>16</bold>, eadq1789 (2024).<pub-id pub-id-type="pmid">39504354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adq1789</pub-id><pub-id pub-id-type="pmcid">PMC11924959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autoimmunity is a hallmark of post-COVID syndrome</article-title><source>J. Transl. Med.</source><year>2022</year><volume>20</volume><fpage>129</fpage><pub-id pub-id-type="pmid">35296346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-022-03328-4</pub-id><pub-id pub-id-type="pmcid">PMC8924736</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Rojas, M. et al. Autoimmunity is a hallmark of post-COVID syndrome. <italic toggle="yes">J. Transl. Med.</italic><bold>20</bold>, 129 (2022).<pub-id pub-id-type="pmid">35296346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-022-03328-4</pub-id><pub-id pub-id-type="pmcid">PMC8924736</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrow</surname><given-names>P</given-names></name><name name-style="western"><surname>Moody</surname><given-names>MA</given-names></name></person-group><article-title>Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies</article-title><source>Immunol. Rev.</source><year>2017</year><volume>275</volume><fpage>62</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">28133804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12504</pub-id><pub-id pub-id-type="pmcid">PMC5299500</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Borrow, P. &amp; Moody, M. A. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. <italic toggle="yes">Immunol. Rev.</italic><bold>275</bold>, 62&#8211;78 (2017).<pub-id pub-id-type="pmid">28133804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12504</pub-id><pub-id pub-id-type="pmcid">PMC5299500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>142</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">35962033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00753-w</pub-id><pub-id pub-id-type="pmcid">PMC9372928</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>23</bold>, 142&#8211;158 (2023).<pub-id pub-id-type="pmid">35962033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00753-w</pub-id><pub-id pub-id-type="pmcid">PMC9372928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>K</given-names></name><etal/></person-group><article-title>High affinity antibodies against influenza characterize the plasmablast response in SLE patients after vaccination</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0125618</fpage><pub-id pub-id-type="pmid">25951191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0125618</pub-id><pub-id pub-id-type="pmcid">PMC4423960</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Kaur, K. et al. High affinity antibodies against influenza characterize the plasmablast response in SLE patients after vaccination. <italic toggle="yes">PLoS ONE</italic><bold>10</bold>, e0125618 (2015).<pub-id pub-id-type="pmid">25951191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0125618</pub-id><pub-id pub-id-type="pmcid">PMC4423960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>The human antibody response to influenza A virus infection and vaccination</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>383</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">30837674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0143-6</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Krammer, F. The human antibody response to influenza A virus infection and vaccination. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>19</bold>, 383&#8211;397 (2019).<pub-id pub-id-type="pmid">30837674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0143-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landais</surname><given-names>E</given-names></name><name name-style="western"><surname>Moore</surname><given-names>PL</given-names></name></person-group><article-title>Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers</article-title><source>Retrovirology</source><year>2018</year><volume>15</volume><fpage>61</fpage><pub-id pub-id-type="pmid">30185183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12977-018-0443-0</pub-id><pub-id pub-id-type="pmcid">PMC6125991</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Landais, E. &amp; Moore, P. L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. <italic toggle="yes">Retrovirology</italic><bold>15</bold>, 61 (2018).<pub-id pub-id-type="pmid">30185183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12977-018-0443-0</pub-id><pub-id pub-id-type="pmcid">PMC6125991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>The humoral response and antibodies against SARS-CoV-2 infection</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>1008</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">35761083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-022-01248-5</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Qi, H., Liu, B., Wang, X. &amp; Zhang, L. The humoral response and antibodies against SARS-CoV-2 infection. <italic toggle="yes">Nat. Immunol.</italic><bold>23</bold>, 1008&#8211;1020 (2022).<pub-id pub-id-type="pmid">35761083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-022-01248-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinite</surname><given-names>B</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>2608</fpage><pub-id pub-id-type="pmid">33510275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-81862-9</pub-id><pub-id pub-id-type="pmcid">PMC7843981</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Trinite, B. et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. <italic toggle="yes">Sci. Rep.</italic><bold>11</bold>, 2608 (2021).<pub-id pub-id-type="pmid">33510275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-81862-9</pub-id><pub-id pub-id-type="pmcid">PMC7843981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Peluso, M. J. et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <italic toggle="yes">Sci. Adv.</italic><bold>7</bold>, eabh3409 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abh3409</pub-id><pub-id pub-id-type="pmcid">PMC8324059</pub-id><pub-id pub-id-type="pmid">34330709</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>DM</given-names></name><name name-style="western"><surname>Whettlock</surname><given-names>EM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Arachchillage</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>RJ</given-names></name></person-group><article-title>The immunology of long COVID</article-title><source>Nat. Rev. Immunol.</source><year>2023</year><volume>23</volume><fpage>618</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">37433988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00904-7</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. &amp; Boyton, R. J. The immunology of long COVID. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>23</bold>, 618&#8211;634 (2023).<pub-id pub-id-type="pmid">37433988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00904-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seibert</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors</article-title><source>Autoimmun. Rev.</source><year>2023</year><volume>22</volume><fpage>103445</fpage><pub-id pub-id-type="pmid">37689093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2023.103445</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Seibert, F. S. et al. Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. <italic toggle="yes">Autoimmun. Rev.</italic><bold>22</bold>, 103445 (2023).<pub-id pub-id-type="pmid">37689093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2023.103445</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tesch</surname><given-names>F</given-names></name><etal/></person-group><article-title>Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study</article-title><source>Clin. Rheumatol.</source><year>2023</year><volume>42</volume><fpage>2905</fpage><lpage>2914</lpage><pub-id pub-id-type="pmid">37335408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-023-06670-0</pub-id><pub-id pub-id-type="pmcid">PMC10497688</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Tesch, F. et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. <italic toggle="yes">Clin. Rheumatol.</italic><bold>42</bold>, 2905&#8211;2914 (2023).<pub-id pub-id-type="pmid">37335408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-023-06670-0</pub-id><pub-id pub-id-type="pmcid">PMC10497688</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jernbom</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>8941</fpage><pub-id pub-id-type="pmid">39414823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-53356-5</pub-id><pub-id pub-id-type="pmcid">PMC11484904</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 8941 (2024).<pub-id pub-id-type="pmid">39414823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-53356-5</pub-id><pub-id pub-id-type="pmcid">PMC11484904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaycox</surname><given-names>JR</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1299</fpage><pub-id pub-id-type="pmid">36894554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-36686-8</pub-id><pub-id pub-id-type="pmcid">PMC9996559</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Jaycox, J. R. et al. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 1299 (2023).<pub-id pub-id-type="pmid">36894554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-36686-8</pub-id><pub-id pub-id-type="pmcid">PMC9996559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maek</surname><given-names>ANW</given-names></name><name name-style="western"><surname>Silachamroon</surname><given-names>U</given-names></name></person-group><article-title>Presence of autoimmune antibody in chikungunya infection</article-title><source>Case Rep. Med.</source><year>2009</year><volume>2009</volume><fpage>840183</fpage><pub-id pub-id-type="pmid">19997520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2009/840183</pub-id><pub-id pub-id-type="pmcid">PMC2787058</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Maek, A. N. W. &amp; Silachamroon, U. Presence of autoimmune antibody in chikungunya infection. <italic toggle="yes">Case Rep. Med.</italic><bold>2009</bold>, 840183 (2009).<pub-id pub-id-type="pmid">19997520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2009/840183</pub-id><pub-id pub-id-type="pmcid">PMC2787058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loza-Tulimowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Semkow</surname><given-names>R</given-names></name><name name-style="western"><surname>Michalak</surname><given-names>T</given-names></name><name name-style="western"><surname>Nowoslawski</surname><given-names>A</given-names></name></person-group><article-title>Autoantibodies in sera of influenza patients</article-title><source>Acta Virol.</source><year>1976</year><volume>20</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">9800</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Loza-Tulimowska, M., Semkow, R., Michalak, T. &amp; Nowoslawski, A. Autoantibodies in sera of influenza patients. <italic toggle="yes">Acta Virol.</italic><bold>20</bold>, 202&#8211;207 (1976).<pub-id pub-id-type="pmid">9800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houen</surname><given-names>G</given-names></name><name name-style="western"><surname>Trier</surname><given-names>NH</given-names></name></person-group><article-title>Epstein-barr virus and systemic autoimmune diseases</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>587380</fpage><pub-id pub-id-type="pmid">33488588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.587380</pub-id><pub-id pub-id-type="pmcid">PMC7817975</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Houen, G. &amp; Trier, N. H. Epstein-barr virus and systemic autoimmune diseases. <italic toggle="yes">Front. Immunol.</italic><bold>11</bold>, 587380 (2020).<pub-id pub-id-type="pmid">33488588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.587380</pub-id><pub-id pub-id-type="pmcid">PMC7817975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Gugliesi, F. et al. Human cytomegalovirus and autoimmune diseases: Where are we? <italic toggle="yes">Viruses</italic><bold>13</bold>, 10.3390/v13020260 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13020260</pub-id><pub-id pub-id-type="pmcid">PMC7914970</pub-id><pub-id pub-id-type="pmid">33567734</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023</article-title><source>CMAJ</source><year>2023</year><volume>195</volume><fpage>E1030</fpage><lpage>E1037</lpage><pub-id pub-id-type="pmid">37580072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.230249</pub-id><pub-id pub-id-type="pmcid">PMC10426348</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Murphy, T. J. et al. The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023. <italic toggle="yes">CMAJ</italic><bold>195</bold>, E1030&#8211;E1037 (2023).<pub-id pub-id-type="pmid">37580072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.230249</pub-id><pub-id pub-id-type="pmcid">PMC10426348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name><etal/></person-group><article-title>Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>2054</fpage><lpage>2063</lpage><pub-id pub-id-type="pmid">32558639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2609.201495</pub-id><pub-id pub-id-type="pmcid">PMC7454076</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Banerjee, A. et al. Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. <italic toggle="yes">Emerg. Infect. Dis.</italic><bold>26</bold>, 2054&#8211;2063 (2020).<pub-id pub-id-type="pmid">32558639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2609.201495</pub-id><pub-id pub-id-type="pmcid">PMC7454076</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>